NCT00686270View on ClinicalTrials.gov

A Long Term Safety Study of Apricitabine in HIV-infected Patients

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
HIV Infections
Interventions
DRUG

apricitabine

Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.

Sponsors

Lead Sponsor

Avexa
All Listed Sponsors
lead

Avexa

INDUSTRY

NCT00686270 - A Long Term Safety Study of Apricitabine in HIV-infected Patients | Biotech Hunter | Biotech Hunter